February 2023 in “Journal of Microencapsulation” The finasteride nanosystem with trehalose is stable and effective for topical hair loss treatment.
January 2023 in “RSC Advances” The study developed accurate, precise, and environmentally friendly methods to measure Finasteride and Tadalafil in a new FDA-approved combination.
December 2022 in “International Journal of Pharmaceutics” The best starting dose for a new finasteride injection is 16.80 mg.
November 2022 in “Asian Journal of Pharmaceutical Research” The hydrogel with Finasteride provides controlled, sustained drug release and improved bioavailability.
November 2022 in “Hair transplant forum international” Finasteride does not cause sexual dysfunction in men with hair loss.
October 2022 in “Biomedicines” Finasteride in male rats causes liver and metabolic issues in their offspring.
October 2022 in “Biomolecules” Allopregnanolone can reduce gut inflammation and normalize neurotransmitter levels after finasteride withdrawal.
September 2022 in “Translational Andrology and Urology” Finasteride may cause lasting sexual and mental health issues, and genetic screening could help prevent them.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
August 2022 in “International journal of membrane science and technology” Finasteride diffuses spontaneously through SDS micelles, suggesting they can replace living cell membranes.
Optimized carriers effectively deliver Finasteride for hair loss treatment.
Public awareness of finasteride's sexual side effects has increased, suggesting healthcare providers should discuss these risks more thoroughly with patients.
May 2022 in “The FASEB Journal” Finasteride may help treat Neutrophil Actin Dysfunction by reducing LSP1 gene activity.
April 2022 in “The Journal of Urology” Men may experience long-term sexual dysfunction after stopping Finasteride.
November 2021 in “Evidencia” Young patients using finasteride may have higher risks of anxiety, depression, and suicidal thoughts.
August 2021 in “Journal of The American Academy of Dermatology” Finasteride treatment changes hormone levels in male pattern baldness patients.
August 2021 in “The Journal of Urology” Finasteride use is strongly linked to sexual dysfunction, especially in young men treating hair loss.
July 2021 in “Reactions Weekly” Man experienced lasting sexual dysfunction from finasteride, but malpractice claim was rejected.
June 2021 in “Archives of Advances in Biosciences” Finasteride reduces sperm count and quality and alters hormone levels in mice.
June 2021 in “Reactions Weekly” Finasteride caused serious side effects and led to six suicides.
April 2021 in “Reactions Weekly” Finasteride increases risk of depression, possibly suicidal thoughts, and sexual dysfunction.
January 2021 in “Zenodo (CERN European Organization for Nuclear Research)” Finasteride-coated microneedles effectively deliver the drug with minimal scalp damage and high stability.
January 2021 in “Asian Journal of Pharmaceutical and Clinical Research” FT-Raman spectroscopy is effective for identifying drug polymorphs, ensuring quality and stability.
November 2020 in “Journal of The American Academy of Dermatology” Finasteride 1 mg every other month works as well as daily dose for hair loss maintenance.
November 2020 in “Reactions Weekly” Finasteride can cause lasting erectile dysfunction, low libido, and depression in some patients.
October 2020 in “Journal of Pharmaceutical Sciences” Topical finasteride with EGCG or TA improves drug release and dermal uptake, potentially treating hair loss effectively.
July 2020 in “CRS 2020 Virtual Annual Meeting” Researchers developed a new skin patch that delivers more finasteride into the skin, potentially improving treatment for hair loss and prostate issues.
Finasteride use is linked to a higher risk of obstructive sleep apnea.
April 2020 in “The FASEB Journal” Finasteride may cause lasting sexual issues by altering specific genes in human cells.
February 2020 in “Pharmacoepidemiology and Drug Safety” Finasteride users have higher odds of certain health issues and lower odds of specific lifestyle factors compared to nonusers.